WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414865
CAS#: 150915-41-6 (free base)
Description: Perospirone Free Base is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.
Hodoodo Cat#: H414865
Name: Perospirone Free Base
CAS#: 150915-41-6 (free base)
Chemical Formula: C23H30N4O2S
Exact Mass: 426.21
Molecular Weight: 426.580
Elemental Analysis: C, 64.76; H, 7.09; N, 13.13; O, 7.50; S, 7.52
Related CAS #: 192052-81-6 (HCl dihydrate) 150915-41-6 (free base) 129273-38-7 (HCl),
Synonym: Perospirone Free Base; Lullan
IUPAC/Chemical Name: 1H-Isoindole-1,3(2H)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, (3aR,7aS)-rel-
InChi Key: FBVFZWUMDDXLLG-HDICACEKSA-N
InChi Code: InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+
SMILES Code: O=C1N(CCCCN2CCN(C3=NSC4=C3C=CC=C4)CC2)C([C@]5([H])CCCC[C@]15[H])=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 426.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Onrust SV, McClellan K. Perospirone. CNS Drugs. 2001;15(4):329-37; discussion 338. doi: 10.2165/00023210-200115040-00006. PMID: 11463136.
2: Haranishi Y, Hara K, Terada T. Antihyperalgesic effects of intrathecal perospirone in a rat model of neuropathic pain. Pharmacol Biochem Behav. 2020 Aug;195:172964. doi: 10.1016/j.pbb.2020.172964. Epub 2020 Jun 3. PMID: 32504731.
3: Kishi T, Iwata N. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. PMID: 23812802.
4: Ohno Y. [Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent]. Nihon Yakurigaku Zasshi. 2000 Oct;116(4):225-31. Japanese. doi: 10.1254/fpj.116.225. PMID: 11084919.
5: de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr Opin Investig Drugs. 2002 Jan;3(1):121-9. PMID: 12054062.
6: Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24. PMID: 28647739.
7: Takeuchi T, Furuta K, Hirasawa T, Masaki H, Yukizane T, Atsuta H, Nishikawa T. Perospirone in the treatment of patients with delirium. Psychiatry Clin Neurosci. 2007 Feb;61(1):67-70. doi: 10.1111/j.1440-1819.2007.01612.x. PMID: 17239041.
8: Masui T, Kusumi I, Takahashi Y, Koyama T. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5. doi: 10.1097/01.ftd.0000185767.59749.bb. PMID: 16418697.
9: Murata Y, Bundo M, Sunaga F, Kasai K, Iwamoto K. DNA Methylation Profiling in a Neuroblastoma Cell Line Exposed to the Antipsychotic Perospirone. Pharmacopsychiatry. 2019 Feb;52(2):63-69. doi: 10.1055/s-0044-101467. Epub 2018 Feb 27. PMID: 29486512.
10: Matsushita M, Egashira N, Harada S, Okuno R, Mishima K, Iwasaki K, Nishimura R, Fujiwara M. Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci. 2005 Oct;99(2):154-9. doi: 10.1254/jphs.fp0050144. Epub 2005 Oct 6. PMID: 16210777.
